Cingulate completed final FDA-required study for CTx-1301 for ADHD

Cingulate (CING) announced that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD. The subjects in the study were given a single 50mg dose of CTx-1301, Cingulate’s highest dosage, to determine if the medication can be taken in fed and fasted states. No serious adverse events were reported. A data readout regarding bioavailability with or without food is expected in 2Q 2025.